INTS vs TDG · $7.7M cap vs P/E 41, rev $8.83B
Intensity Therapeutics, Inc. Common stock (INTS) versus Transdigm Group Incorporated (TDG) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Transdigm Group Incorporated (TDG) is a aerospace & defense company listed on NYSE.
INTS does not have a complete income-statement cache yet.
Latest reported TDG revenue for 2025-09-30 was $8.83B. Net income was $2.07B. Revenue was up 11.2% from 2024-09-30 to 2025-09-30. TDG currently screens at market cap $73.65B and trailing P/E 41.1.
INTS currently screens at market cap $7.7M. TDG currently screens at market cap $73.65B and trailing P/E 41.1.
Not investment advice. Open the INTS and TDG stock pages for the full models.
Not investment advice.